13.98

5.51% +0.73

Pliant Therapeutics Inc (PLRX)

Overview News Price History Option Chain Financials Discussions Forecast

Pliant Therapeutics Inc stock is currently priced at $13.98, with a 24-hour trading volume of 299.02K. It has seen a +5.51% increased in the last 24 hours and a -3.12% declined in the past month. The chart indicates a potential bullish trend, as the stock is above the $13.09 pivot point. If it approaches the $14.14 resistance level, significant changes may occur.

Previous Close:

$13.25

Open:

$13.8

24h Volume:

299.02K

Market Cap:

$843.26M

Revenue:

$5.03M

Net Income/Loss:

$-161.34M

P/E Ratio:

-5.1022

EPS:

-2.74

Net Cash Flow:

$-117.28M

1W Performance:

+18.37%

1M Performance:

-3.12%

6M Performance:

-13.22%

1Y Performance:

-41.51%

1D Range:

$13.58

$14.09

52W Range:

$11.21

$24.74

Pliant Therapeutics Inc Stock (PLRX) Company Profile

Name

Pliant Therapeutics Inc

Sector

Healthcare (1213)

Industry

Biotechnology (699)

Phone

650 481 6770

Address

260 Littlefield Avenue, South San Francisco, CA

Employee

Twitter

Next Earnings Date

2024-05-14

Latest SEC Filings

PLRX's Discussions on Twitter

Pliant Therapeutics Inc Stock (PLRX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
May-18-23	Initiated	Canaccord Genuity	Buy
Apr-13-23	Initiated	Robert W. Baird	Outperform
Dec-14-22	Initiated	Stifel	Buy
Dec-07-22	Initiated	JP Morgan	Overweight
Sep-01-22	Initiated	Citigroup	Buy
Jul-20-22	Initiated	SVB Leerink	Outperform
May-25-22	Initiated	Cantor Fitzgerald	Overweight
Dec-10-21	Initiated	Oppenheimer	Outperform
Nov-24-21	Initiated	RBC Capital Mkts	Outperform
Nov-03-21	Initiated	H.C. Wainwright	Buy
Apr-20-21	Initiated	BTIG Research	Buy
Apr-05-21	Initiated	Citigroup	Buy
Jun-29-20	Initiated	Citigroup	Buy
Jun-29-20	Initiated	Cowen	Outperform
Jun-29-20	Initiated	Needham	Buy
Jun-29-20	Initiated	Piper Sandler	Overweight

View All

Pliant Therapeutics Inc Stock (PLRX) Latest News

Earnings Preview: Pliant Therapeutics, Inc. (PLRX) Q4 Earnings Expected to Decline

Zacks Investment Research

Why Air Products and Chemicals Shares Are Trading Lower By Around 15%? Here Are Other Stocks Moving In Monday's Mid-Day Session

Benzinga

HC Wainwright & Co. Maintains Buy Rating for Pliant Therapeutics: Here's What You Need To Know

Benzinga

The Latest Analyst Ratings for Pliant Therapeutics

Benzinga

Is a Surprise Coming for Pliant Therapeutics (PLRX) This Earnings Season?

Zacks Investment Research

Pliant Therapeutics, Inc. (PLRX) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

Zacks Investment Research

Pliant Therapeutics Inc Stock (PLRX) Financials Data

Pliant Therapeutics Inc (PLRX) Revenue 2024

PLRX reported a revenue (TTM) of $5.03 million for the quarter ending June 30, 2023, a -48.95% decline year-over-year.

Pliant Therapeutics Inc (PLRX) Net Income 2024

PLRX net income (TTM) was -$161.34 million for the quarter ending December 31, 2023, a -30.83% decrease year-over-year.

Pliant Therapeutics Inc (PLRX) Cash Flow 2024

PLRX recorded a free cash flow (TTM) of -$117.28 million for the quarter ending December 31, 2023, a -21.67% decrease year-over-year.

Pliant Therapeutics Inc (PLRX) Earnings per Share 2024

PLRX earnings per share (TTM) was -$2.76 for the quarter ending December 31, 2023, a +7.07% growth year-over-year.

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrotic in the United States. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins, which has completed Phase Ia single ascending dose/ multiple ascending dose trails and Phase Ib proof-of-mechanism trials for the treatment of idiopathic pulmonary fibrosis and primary sclerosing cholangitis. The company also develops PLN-1474, small-molecule selective inhibitor of avß1, which is Phase 1 clinical trials for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis. Pliant Therapeutics, Inc. was founded in 2015 and is based in South San Francisco, California.